An interventional study of Fetal Aortic Valvuloplasty Procedure and Emerge Monorail and Over-The-Wire PTCA Dilatation Catheter in Hypoplastic Left Heart Syndrome, sponsored by Mauro H. Schenone. Enrolling by invitation at 1 site in United States. Open to female participants aged Up to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-01.
Sponsored by Mauro H. Schenone · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Hypoplastic Left Heart Syndrome with a site in United States — 6 open to participants now, 10 under way, 1 of them phase 3. Hypoplastic Left Heart Syndrome · United States.
Among the 44 studies in Hypoplastic Left Heart Syndrome with a site in United States, this one is the 5th largest by planned enrollment of the 26 interventional ones that give a count, is the only one that started in 2027, is one of 8 with no phase, and was the 41st registered.
67 studies on the registry are indexed under Hypoplastic Left Heart Syndrome; 12 are open to participants now.
Browse Hypoplastic Left Heart Syndrome studies →6 of the 44 studies in Hypoplastic Left Heart Syndrome with a site in United States are open now. Recruiting first, the newest first:
HeartWorks, Inc. · Sites in United States
Ages 0+
Queen Silvia Children's Hospital, Gothenburg, Sweden · Sites in United States, Austria, Canada and 5 more countries
Ages 23 wk–31 wk
Nationwide Children's Hospital · Sites in United States
Children's Hospital Medical Center, Cincinnati · Sites in United States, Canada, United Kingdom
Ages up to 15 mo
Emory University · Sites in United States
Ages up to 1
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 9 Hypoplastic Left Heart Syndrome studies recruiting now, 3 set no upper age limit and 6 stop at 75 or younger; 9 take children under 18; none take healthy volunteers.
This study: Up to 45 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 7 · Phase 3 2
First in 2001; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is above the median of 30 across 41 interventional studies indexed under Hypoplastic Left Heart Syndrome.
Median enrollment 30 across the 26 interventional studies, 96 across the 18 observational. Of the 32 that completed or were terminated, 7 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 44 have an industry lead sponsor. The 10 most frequent:
Mauro H. Schenone is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Mauro H. Schenone has 1 study filed under Hypoplastic Left Heart Syndrome — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 44 studies in Hypoplastic Left Heart Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this research is to investigate the best way to manage evolving hypoplastic left heart syndrome (HLHS).
The condition occurs when part of the heart doesn't develop properly so the heart is not able to pump blood around the body effectively. Babies born with this condition require surgery and are often left with a lifelong heart disability. A number of babies with this condition will die during pregnancy or within the first year of life (approximately 10-40%). We are investigating a treatment given during pregnancy in which a balloon is used to increase the size of the baby's aortic valve. The aortic valve function is to allow easy flow from the heart to the body and prevent blood from returning to the heart (regurgitation). This is called fetal aortic valvuloplasty. A number of studies have shown promising results, including a higher of the baby surviving with both sides of the heart functioning (as opposed to only the right side), this may also lead to longer survival with a better quality of life. However, we do not have enough information to say this is always the best way to manage the condition. Currently, parents of babies with this condition, who meet certain eligibility criteria, are offered fetal aortic valvuloplasty during pregnancy. The alternative option is not to intervene during pregnancy but instead monitor the baby with regular ultrasounds. We call this conservative management.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Evolving hypoplastic left heart syndrome defined as depressed left ventricle systolic and at least one of the following:
Potential for a technically successful and postnatal biventricular outcome defined as left ventricle long axis Z-score equal or greater than -2 PLUS at least 4 of the following 5 criteria:
Exclusion Criteria
Cases with all the following criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Women diagnosed with HLHS will undergo fetal aortic valvuloplasty between 21 and 29 weeks gestation.
Procedure: Fetal Aortic Valvuloplasty Procedure · Device: Emerge Monorail and Over-The-Wire PTCA Dilatation Catheter · Device: Trek RX and Mini Trek RX Coronary Dilatation Catheter
Women diagnosed with HLHS will undergo expectant management with postnatal surgery.
Treatment given during pregnancy in which a balloon is used to increase the size of the baby's aortic valve in vitro.
Balloon Catheter
Coronary Dilation Catheter
Number of cases in which the procedure was successful
Procedure success defined as the aortic valve was crossed and the balloon inflated with clear evidence of improvement of blood flow through the aortic valve and or new aortic valve regurgitation
Time frame: Baseline
Number of cases in which a biventricular repair was achieved
Time frame: Baseline
Number cases with pulmonary hypertension
Time frame: Baseline
Number of cases delivered prematurely
Time frame: Baseline
Number of cases with perinatal death
Time frame: Baseline
Number of maternal complications
Time frame: Baseline
Plan to share: No
Start is estimated for Jan 2027; primary completion for Jul 2036, 114 months later.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hypoplastic Left Heart Syndrome →
Mauro H. Schenone